XEN1101 as Adjunctive Therapy in Focal-Onset Epilepsy, with an Open-Label Extension

Focusing on new patient treatment possibilities.


The X-TOLE Study is evaluating an oral investigational drug called XEN1101 for people with focal-onset epilepsy. You will be able to continue taking your current anti-seizure medication along with the investigational drug. XEN1101 is a novel, selective KV7 potassium channel modulator. This study will help determine if XEN1101 reduces seizures in people with focal-onset epilepsy.

Xenon Pharmaceuticals, Inc. is developing XEN1101 and is sponsoring the X-TOLE Study. NCGS, Inc. is the Clinical Research Organization managing the clinic’s participating in the X-TOLE Study on behalf of Xenon.

If you are between the ages of 18 and 75 and have had a focal-onset or partial-onset epilepsy diagnosis for 2 or more years, you may be eligible to participate in a worldwide study to try the investigational drug, XEN1101. If you qualify, you will receive study-related care from a study doctor and travel support to attend the study visits.

*The study doctor will also check other requirements to see if you’re eligible to participate.

*You don’t need health insurance or a doctor referral to participate in this study.

To see if you meet the criteria, click here

Copyright NCGS – All rights reserved